[Cardiovascular preventive recommendations. PAPPS 2020 update]

Domingo Orozco-Beltrán, Carlos Brotons Cuixart, José Juan Alemán Sánchez, José Ramón Banegas Banegas, Ana M Cebrián-Cuenca, Vicente F Gil Guillen, Enrique Martín Rioboó, Jorge Navarro Pérez, Domingo Orozco-Beltrán, Carlos Brotons Cuixart, José Juan Alemán Sánchez, José Ramón Banegas Banegas, Ana M Cebrián-Cuenca, Vicente F Gil Guillen, Enrique Martín Rioboó, Jorge Navarro Pérez

Abstract

The recommendations of the semFYC's Program for Preventive Activities and Health Promotion (PAPPS) for the prevention of cardiovascular diseases (CVD) are presented. The following sections are included: Epidemiological review, where the current morbidity and mortality of CVD in Spain and its evolution as well as the main risk factors are described; Cardiovascular (CV) risk tables and recommendations for the calculation of CV risk; Main risk factors such as arterial hypertension, dyslipidemia and diabetes mellitus, describing the method for their diagnosis, therapeutic objectives and recommendations for lifestyle measures and pharmacological treatment; Indications for antiplatelet therapy, and recommendations for screening of atrial fibrillation. The quality of testing and the strength of the recommendation are included in the main recommendations.

Keywords: Atencion primaria; Cardiovascular diseases; Diabetes mellitus; Enfermedades cardiovasculares; Family medicine; Medicina de familia; Preventive activities; Primary care.

Copyright © 2020 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved.

References

    1. Instituto Nacional de Estadística. INEbase [consultado 30 Jul 2020]. Disponible en:
    1. Soriano J.B., Rojas-Rueda D., Alonso J., Antó J.M., Cardona P.J., Fernández E. La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016. Med Clin (Barc). 2018;151:171–190.
    1. Timmis A., Townsend N., Gale C.P., Torbica A., Lettino M., Petersen S.E. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41:12–85. doi: 10.1093/eurheartj/ehz859.
    1. Banegas J.R., Graciani A., Guallar-Castillón P., Gutiérrez-Hisac J., López-García E., Otero-Rodríguez A. Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid; Madrid: 2011. Estudio de Nutrición y Riesgo Cardiovascular en España (ENRICA).
    1. Menéndez E., Delgado E., Fernández-Vega F., Prieto M.A., Bordiú E., Calle A. Prevalence, diagnosis treatment, and control of hypertension in Spain. Results of the Di@bet.es Study. Rev Esp Cardiol (Engl. Ed.). 2016;69:572–578. doi: 10.1016/j.rec.2015.11.034.
    1. Barrios V., Escobar C., Alonso-Moreno F.J., Prieto M.A., Pallares V. Evolution of clinical profile, treatment and blood pressure control in treated hypertensive patients according to the sex from 2002 to 2010 in Spain. J Hypertens. 2015;33:1098–1107.
    1. Banegas J.R., Navarro-Vidal B., Ruilope L.M., de la Cruz J.J., López-García E., Rodríguez-Artalejo H. Trends in hypertension control among the older population of Spain from 2000 to 2001 to 2008 to 2010: Role of frequency and intensity of drug treatment. Circ Cardiovasc Qual Outcomes. 2015;8:67–76.
    1. Banegas J.R., de la Cruz J.J., Graciani A., López-García E., Gijón- Conde T., Ruilope L.M. Impact of ambulatory blood pressure monitoring on reclassification of hypertension prevalence and control in older people in Spain. J Clin Hypertens (Greenwich). 2015;17:453–461.
    1. Grau M., Elosua R., Cabrera de León A., Guembe M.J., Baena-Díez J.M., Vega Alonso T. Hactores de riesgo cardiovascular en España en la primera década del siglo xxi: análisis agrupado con datos individuales de 11 estudios de base poblacional, estudio DARIOS. Rev Esp Cardiol. 2011;64:295–304.
    1. Martín-Rioboó E., García Criado E., Perula de Torres L.A., Cea- Calvo L., Anguita Sánchez M., López Granados A. Prevalencia de hipertroÞa ventricular izquierda Þbrilación auricular y enfermedad cardiovascular en hipertensos de Andalucía. Estudio PREHVIA. Med Clin (Barc). 2009;132:243–250.
    1. Guallar-Castillón P., Gil-Montero M., León-Muñoz L.M., Graciani A., Bayan-Bravo A., Taboada J.M. Magnitud y manejo de la hipercolesterolemia en la población adulta de España, 2008-2010: el estudio ENRICA. Rev Esp Cardiol. 2012;65:551–558.
    1. Pedro-Botet J., Mostaza J.M., Pintó X., Banegas J.R., en Nombre del Grupo de Investigadores EDICONDIS-ULISEA Consecución del objetivo terapéutico del colesterol de las lipoproteínas de baja densidad en las unidades de lípidos y riesgo vascular de la Sociedad Española de Arteriosclerosis. Clin Investig Arterioscler. 2013;25:155–163.
    1. Soriguer H., Goday A., Bosch-Comas A., Bordiu E., Calle-Pascual A., Carmena R. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Di@bet.es Study. Diabetologia. 2012;55:88–93.
    1. Franch-Nadal J, Mata-Cases M, Vinagre I, Patitucci F, Hermosilla E, Casellas A, et al. Differences in the cardiometabolic control in type 2 diabetes according to gender and the presence of cardiovascular disease: results from the econtrol study. Int J Endocrinol. 2014;2014:131709. doi: 10.1155/2014/131709.
    1. Hernández-Bergés D., Cabrera de León A., Sanz H., Elosua R., Guembe M.J., Alzamora M. Síndrome metabólico en España: prevalencia y riesgo coronario asociado a la deÞnición armonizada y a la propuesta por la OMS. Estudio DARIOS. Rev Esp Cardiol. 2012;65:241–248.
    1. Amor A.J., Masana L., Soriguer H., Goday A., Calle-Pascual A., Gaztambide S., en nombre del grupo de estudio Di@bet.Es Estimación del riesgo cardiovascular en España según la guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica. Rev Esp Cardiol. 2015;68:417–425.
    1. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L. 2016 European guideliness on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–2381.
    1. Royo-Bordonada M.A., Armario P., Lobos Bejarano J.M., Pedro-Botet J., Villar Alvarez F., Elosua R., en nombre del Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC) Adaptación española de las guías europeas de 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. Rev Esp Salud Publica. 2016;90:e1–e24.
    1. Piepoli M.F., Abreu A., Albus C., Ambrosetti M., Brotons C., Catapano A.L. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol. 2020;27:181–205.
    1. Baena-Diez J.M., Subirana I., Ramos R., Gómez de la Cámara A., Elosua R., Vila J. Evaluación de la validez de las funciones SCORE de bajo riesgo y calibrada para población española en las cohortes FRESCO. Rev Esp Cardiol. 2018;71:274–282.
    1. Vega Alonso A.T., Ordax Díez A., Lozano Alonso J.E., Álamo Sanz R., Lleras Muñoz S., García Palomar P. Validación del índice SCORE y el SCORE para personas mayores en la cohorte de riesgo de enfermedad cardiovascular en Castilla y León. Hipertens Riesgo Vasc. 2019;36:184–192.
    1. Bertomeu-González V., Soriano Maldonado C., Bleda-Cano J., Carrascosa-Gonzalvo S., Navarro-Perez J., López-Pineda A. Predictive validity of the risk SCORE model in a Mediterranean population with dyslipidemia. Atherosclerosis. 2019;290:80–86.
    1. Marrugat J., Solanas P., d’Agostino R., Sullivan L., Ordovas J., Cordón F. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253–261.
    1. Marrugat J., Subirana I., Comin E., Cabezas C., Vila J., Elosua R. Validity of an adaptation of the Framingham cardiovascular risk function: The VERIFICA study. J Epidemiol Community Health. 2007;61:40–47.
    1. Marrugat J., Subirana I., Ramos R., Vila J., Marín-Ibañez A., Guembe M.J. Derivation and validation of a set of 10-year cardiovascular risk predictive functions in Spain: The FRESCO Study. Prev Med. 2014;61:66–74.
    1. Brotons C., Moral I., Fernández D., Puig M., Calvo Bonacho E., Martínez Muñoz P. Estimation of Lifetime Risk of Cardiovascular Disease (IBERLIFERISK): A new tool for cardiovascular disease prevention in Primary Care. Rev Esp Cardiol (Engl. Ed.). 2019;72:562–568.
    1. Jaspers N.E.M., Blaha M.J., Matsushita K., van der Schouw Y.T., Wareham N.J., Khaw K.T. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Eur Heart J. 2020;41:1190–1199.
    1. Berkelmans G.F.N., Gudbjörnsdottir S., Visseren F.L.J., Wild S.H., Franzen S., Chalmers J. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with type 2 diabetes mellitus. Eur Heart J. 2019;40:2899–2906.
    1. Quesada J.A., Lopez-Pineda A., Gil-Guillén V.F., Durazo-Arvizu R., Orozco-Beltrán D., López-Domenech A. Machine learning to predict cardiovascular risk. Int J Clin Pract. 2019;73:e13389.
    1. Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596–e646.
    1. Lin J.S., Evans C.S., Johnson E., Redmon N., Coppola E.L., Smith N. Nontraditional risk factors in cardiovascular risk assessment: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320:281–297.
    1. Brotons Cuixart C., Alemán Sánchez J.J., Banegas Banegas J.R., Fondón León C., Lobos-Bejarano J.M., Martín Rioboó E., Grupo de Prevención Cardiovascular del PAPPS Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2018. Aten Primaria. 2018;50(Suppl 1):4–28.
    1. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. ESC Scientific Document Group 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.
    1. Bakris G.L., Sorrentino M.J. 3rd ed. Elsevier; Philadelphia: 2018. Hypertension. A companyon to Braunwald's Heart Disease. editores.
    1. Pickering T.G., Hall J.E., Appel L.J., Falkner B.E., Graves J., Hill M.N. Recommendations for blood pressure measurement in humans and experimental animals: part 1: Blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697–716.
    1. Stergiou G., Mengden T., Padfield P.L., Parati G., O’Brien E., Working Group on Blood Pressure Monitoring of the European Society of Hypertension Self-monitoring of blood pressure at home. BMJ. 2004;329:870–871.
    1. Parati G., Stergiou G., O’Brien E., Asmar R., Beilin L., Bilo G. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359–1366.
    1. Myers M.G., Godwin M., Dawes M., Kiss A., Tobe S.W., Kaczorowski J. Measurement of blood pressure in the office: Recognizing the problem and proposing the solution. Hypertension. 2010;55:195–200.
    1. Whelton P.K., Carey R.M., Aronow W.S., Casey D.E., Jr., Collins K.J., Dennison Himmelfarb C. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–1324.
    1. Wright J.T., Jr., Williamson J.D., Whelton P.K., Snyder J.K., Sink K.M., Rocco M.V., SPRINT Research Group Randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116.
    1. Gijón-Conde T., Sánchez-Martínez M., Graciani A., Cruz J.J., López-García E., Ortolá R. Impact of the European and American guidelines on hypertension prevalence, treatment, and cardiometabolic goals. J Hypertens. 2019;37:1393–1400.
    1. Schwalm J.D., McCready T., Lopez-Jaramillo P., Yusoff K., Attaran A., Lamelas P. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): A cluster-randomised controlled trial. Lancet. 2020;394:1231–1242.
    1. Guirguis-Blake J.M., Evans C.V., Webber E.M., Coppola E.L., Perdue L.A., Soulsby Weyrich M. Agency for Healthcare Research and Quality U.S. Department of Health and Human Services; Rockville, MD: 2020. Screening for hypertension in adults: A systematic evidence review for the U.S. Preventive Services Task Force.
    1. Clement D.L., de Buyzere M.L., de Bacquer D.A., de Leeuw P.W., Duprez D.A., Fagard R.H. Office versus ambulatory pressure study investigators prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–2415.
    1. Sega R., Facchetti R., Bombelli M., Cesana G., Corrao G., Grassi G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777–1783.
    1. Hansen T.W., Jeppesen J., Rasmussen S., Ibsen H., Torp-Pedersen C. Ambulatory blood pressure and mortality: A population-based study. Hypertension. 2005;45:499–504.
    1. Kikuya M., Ohkubo T., Asayama K., Metoki H., Obara T., Saito S. Ambulatory blood pressure and 10-year risk of cardiovascular and non cardiovascular mortality: The Ohasama study. Hypertension. 2005;45:240–245.
    1. Boggia J., Li Y., Thijs L., Hansen T.W., Hansen T.W., Kikuya M., Björklund-Bodegård K. Prognostic accuracy of day versus night ambulatory blood pressure: A cohort study. Lancet. 2007;370:1219–1229.
    1. Staessen J.A., Li Y., Hara A., Asayama K., Dolan E., O’Brien E. Blood pressure measurement. Anno 2016. Am J Hypertens. 2017;30:453–463.
    1. Banegas J.R., de la Cruz J.J., Graciani A., López-García E., Gijón-Conde T., Ruilope L.M. Impact of ambulatory blood pressure monitoring on reclassification of hypertension prevalence and control in older people in Spain. J Clin Hypertens (Greenwich). 2015;17:453–461.
    1. Beyhaghi H., Viera A.J. Comparative cost-effectiveness of clinic, home, or ambulatory blood pressure measurement for hypertension diagnosis in US adults. A modeling study. Hypertension. 2019;73:121–131.
    1. Martín-Riobó E., Pérula de Torres L.A., Lobos-Bejarano J.M., Brotons Cuixart C., García Criado E.I., MAMPA, PAPPS Study Groups Knowledge, availability, and use of ambulatory and home blood pressure monitoring in primary care in Spain: The MAMPA study. J Hypertens. 2018;36:1051–1058.
    1. National Institute for Health and Clinical Excellence. Hypertension in adults: Diagnosis and management NICE guideline. Published: 28 August 2019 [consultado 30 Jul 2020] Disponible en:
    1. Unger T., Borghi C., Charchar F., Khan N.A., Poulter N.R., Prabhakaran D. 2020 International Society of Hypertension Global. Hypertension Practice Guidelines. Hypertension. 2020;75:1334–1357.
    1. Ziv A., Vogel O., Keret D., Pintov S., Bodenstein E., Wolkomir K. Comprehensive Approach to Lower Blood Pressure (CALM- BP): A randomized controlled trial of a multifactorial lifestyle intervention. J Hum Hypertens. 2013;27:594–600.
    1. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–2381.
    1. Lim G.B. Hypertension: Low sodium and DASH diet to lower blood pressure. Nat Rev Cardiol. 2018;15:68.
    1. Estruch R., Ros E., Salas-Salvadó J., Covas M.I., Corella D., Arós F., PREDIMED Study Investigators Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378:e34.
    1. Domenech M., Román P., Lapetra J., García de la Corte F.J., Sala-Vila A. Mediterranean diet reduces 24- hour ambulatory blood pressure, blood glucose, and lipids: One-year randomized, clinical trial. Hypertension. 2014;64:69–76.
    1. Lana A., Banegas J.R., Guallar-Castillón P., Rodríguez-Artalejo F., Lopez-Garcia E. Association of dairy consumption and 24-hour blood pressure in older adults with hypertension. Am J Med. 2018;131:1238–1249.
    1. Ebrahim S., Taylor F., Ward K., Beswick A., Burke M., Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev. 2011:CD001561.
    1. Ettehad D., Emdin C.A., Kiran A., Anderson S.G., Callender T., Emberson J. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 2016;387:957–967.
    1. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials. J Hypertens. 2014;32:2285–2295.
    1. Sundstrom J., Arima H., Jackson R., Turnbull F., Rahimi K., Chalmers J., Blood Pressure-Lowering Treatment Trialists’ Collaboration Effects of blood pressure reduction in mild hypertension: A systematic review and meta-analysis. Ann Intern Med. 2015;162:184–191.
    1. Lonn E.M., Bosch J., Lopez-Jaramillo P., Zhu J., Liu L., Pais P. HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009–2020.
    1. Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D., Stoyanovsky V., HYVET Study Group Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–1898.
    1. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35:2150–2160.
    1. Brotons Cuixart C. Mejoremos la predicción del riesgo coronario en España [Let's improve coronary risk prediction in Spain]. Rev Esp Cardiol. 2003;56(3):225-7.
    1. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922–944.
    1. Bohm M., Schumacher H., Teo K.K., Lonn E.M., Mahfoud F., Mann J.F.E. Achieved blood pressure and cardiovascular outcomes in high-risk patients: Results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226–2237.
    1. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5 head-to-head comparisons of various classes of antihypertensive drugs —overview and meta-analyses. J Hypertens. 2015;33:1321–1324.
    1. Mensah G.A., Bakris G. Treatment and control of high blood pressure in adults. Cardiol Clin. 2010;28:609–622.
    1. Roas S., Bernhart F., Schwarz M., Kaiser W., Noll G. Antihypertensive combination therapy in primary care offices: Results of a cross-sectional survey in Switzerland. Int J Gen Med. 2014;7:549–556.
    1. Egan B.M., Bandyopadhyay D., Shaftman S.R., Wagner C.S., Zhao Y., Yu-Isenberg K.S. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59:1124–1131.
    1. Volpe M., Gallo G. To whom recommend intensive treatment for hypertension? Eur Heart J Supplements. 2020;22(Suppl E):E167–E172.
    1. Sherrill B., Halpern M., Khan S. Zhang Panjabi Sl. Single-pill vs free-equivalent combination therapies for hypertension: A meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898–909.
    1. Ambrosius W.T., Sink K.M., Foy C.G., Berlowitz D.R., Cheung A.K., Cushman W.C. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT) Clin Trials. 2014;11:532–546.
    1. Cushman W.C., Grimm R.H., Jr., Cutler J.A., Evans G.W., Capes S., Corson M.A. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i–i55.
    1. Kario K., Morisawa Y., Sukonthasarn A., Turana Y., Chia Y.C., Park S., Hypertension Cardiovascular Outcome Prevention Evidence in Asia (HOPE Asia) Network COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network. J Clin Hypertens (Greenwich). 2020;9 doi: 10.1111/jch.13917.
    1. Mancia G., Rea F., Ludergnani M., Apolone G., Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431–2440.
    1. Ruilope L.M., Tamargo J., Ruiz-Hurtado G. Renin-angiotensin system inhibitors in the COVID-19 pandemic: Consequences of antihypertensive drugs. Eur Heart J. 2020;41:2067–2069.
    1. Grupo de Hipertensión de SEMFYC. Posicionamiento sobre hipertensión y coronavirus [consultado 10 Jul 2020]. Disponible en:
    1. Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial. Comunicado urgente de la SEH-LELHA sobre el manejo del paciente hipertenso en tratamiento con fármacos que bloquean el sistema renina- angiotensina-aldosterona y su relación con el covid-19 [consultao 10 Jul 2020]. Disponible en:
    1. McManus R.J., Mant J., Haque M.S., Bray E.P., Bryan S., Greenfield S.M. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: The TASMIN-SR randomized clinical trial. JAMA. 2014;312:799–808.
    1. Tucker K.L., Sheppard J.P., Stevens R., Bosworth H.B., Bove A., Bray E.P. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Med. 2017;14:e1002389.
    1. Coca A., Agabiti-Rosei E., Cifkova R., Manolis A.J., Redón J., Mancia G. The polypill in cardiovascular prevention: Evidence, limitations and perspective-position paper of the European Society of Hypertension. J Hypertens. 2017;35:1546–1553.
    1. Márquez Contreras E., Márquez Rivero S., Rodríguez García E., López-García-Ramos L., Carlos Pastoriza Vilas J., Baldonedo Suárez A., Compliance Group of Spanish Society of Hypertension (SEH-LELHA) Specific hypertension smartphone application to improve medication adherence in hypertension: a cluster-randomized trial. Curr Med Res Opin. 2019;35:167–173.
    1. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
    1. Naci H., Brugts J., Ades T. Comparative tolerability and harms of individual statins: A study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6:390–399.
    1. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
    1. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Cholesterol Treatment Trialists’ (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet. 2008;371:117–125.
    1. Hackam D.G., Woodward M., Newby L.K., Bhatt D.L., Shao M., Smith E.E. Statins and intracerebral hemorrhage: Collaborative systematic review and meta-analysis. Circulation. 2011;124:2233–2242.
    1. Savarese G., Gotto A.M., Jr., Paolillo S., d’Amore C., Losco T., Musella F. Benefits of statins in elderly subjects without established cardiovascular disease: A meta-analysis. J Am Coll Cardiol. 2013;62:2090–2099. Erratum in: J Am Coll Cardiol. 2014;63(11):1122.
    1. Kostis W.J., Cheng J.Q., Dobrzynski J.M., Cabrera J., Kostis J.B. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59:572–582.
    1. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
    1. Giugliano R.P., Cannon C.P., Blazing M.A., Nicolau J.C., Corbalán R., Špinar J., IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: Results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Circulation. 2018;137:1571–1582.
    1. Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., FOURIER Steering Committee and Investigators Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
    1. Schwartz G.G., Steg P.G., Szarek M., Bhatt D.L., Bittner V.A., Diaz R., ODYSSEY OUTCOMES Committees and Investigators Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–2107.
    1. Bonaca M.P., Nault P., Giugliano R.P., Keech A.C., Pineda A.L., Kanevsky E. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) Circulation. 2018;137:338–350.
    1. Jukema J.W., Szarek M., Zijlstra L.E., de Silva H.A., Bhatt D.L., Bittner V.A. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74:1167–1176.
    1. O’Donoghue M.L., Fazio S., Giugliano R.P., Stroes E.S.G., Kanevsky E., Gouni-Berthold I. Lipoprotein(a) PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483–1492.
    1. Bittner V.A., Szarek M., Aylward P.E., Bhatt D.L., Diaz R., Edelberg J.M. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75:133–144.
    1. Nicholls S.J., Puri R., Anderson T., Ballantyne C.M., Cho L., Kastelein J.J. Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial. JAMA. 2016;316:2373–2384.
    1. Cao Y.X., Liu H.H., Dong Q.T., Li S., Li J.J. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. Diabetes Obes Metab. 2018;20:1391–1398.
    1. Giugliano R.P., Mach F., Zavitz K., Kurtz C., Im K., Kanevsky E. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377:633–643.
    1. Harvey P.D., Sabbagh M.N., Harrison J.E., Ginsberg H.N., Chapman M.J., Manvelian G. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized phase 2 and 3 controlled trials: A meta-analysis of individual patient data. Eur Heart J. 2018;39:374–381.
    1. Dobrzynski J.M., Kostis J.B., Sargsyan D., Zinonos S., Kostis W.J. Effect of cholesterol lowering with statins or proprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysis. J Clin Lipidol. 2018;12:728–733.
    1. Faselis C., Imprialos K., Grassos H., Pittaras A., Kallistratos M., Manolis A. Is very low LDL-C harmful? Curr Pharm Des. 2018;24:3658–3664.
    1. Alexander D.D., Miller P.E., van Elswyk M.E., Kuratko C.N., Bylsma L.C. A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. Mayo Clin Proc. 2017;92:15–29.
    1. Abdelhamid A.S., Brown T.J., Brainard J.S., Biswas P., Thorpe G.C., Moore H.J. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;7:CD003177. Update in: Cochrane Database Syst Rev. 2018 Nov 30;11:CD003177.
    1. Wen Y.T., Dai J.H., Gao Q. Effects of Omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: A meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2014;24:470–475.
    1. Mozaffarian D., Rimm E.B. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA. 2006;296:1885–1889.
    1. Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Ketchum S.B., REDUCE-IT Investigators Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
    1. Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Jiao L., REDUCE-IT Investigators Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am Coll Cardiol. 2019;74:1159–1161.
    1. Banegas J.R., Graciani A., Guallar-Castillón P., Gutiérrez-Fisac J.L., Luz León Muñoz L., López-García E. Departamento de Medicina Preventiva y Salud Pública. Universidad Autónoma de Madrid; Madrid: 2011. Estudio de Nutrición y Riesgo Cardiovascular en España (ENRICA)
    1. Alvarez-Guisasola F., Cebrián-Cuenca A.M., Cos X., Ruiz-Quintero M., Millaruelo J.M., Cahn A. Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real-life clinical practice. Diabetes Metab Res Rev. 2018;34
    1. Soriguer F., Goday A., Bosch-Comas A., Bordiú E., Calle-Pascual A., Carmena R. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Di@bet.es Study. Diabetologia. 2012;55:88–93.
    1. Mirahmadizadeh A., Fathalipour M., Mokhtari A.M., Zeighami S., Hassanipour S., Heiran A. The prevalence of undiagnosed type 2 diabetes and prediabetes in Eastern Mediterranean region (EMRO): A systematic review and meta-analysis [published correction appears in Diabetes Res Clin Pract. 2020 Jul 3;:108276] Diabetes Res Clin Pract. 2020;160:107931.
    1. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas 9 th edition. Diabetes Res Clin Pract. 2019;157:107843.
    1. Rojo-Martínez G., Valdés S., Soriguer F., Vendrell J., Urrutia I., Pérez V. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study. Sci Rep. 2020;10:2765. doi: 10.1038/s41598-020-59643-7.
    1. Vinagre I., Mata-Cases M., Hermosilla E., Morros R., Fina F., Rosell M. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain) Diabetes Care. 2012;35:774–779.
    1. Rao Kondapally Seshasai S., Kaptoge S., Thompson A., Di Angelantonio E., Gao P., Sarwar N. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–841.
    1. Ford E.S., Zhao G., Li C. Pre-diabetes and the risk for cardiovascular disease: A systematic review of the evidence. J Am Coll Cardiol. 2010;55:1310–1317.
    1. Di Angelantonio E., Gao P., Khan H., Butterworth A.S., Wormser D., Kaptoge S. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014;311:1225–1233.
    1. Nathan D.M., McGee P., Steffes M.W., Lachin J.M. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 2014;63:282–290.
    1. Selph S., Dana T., Blazina I., Bougatsos C., Patel H., Chou R. Screening for type 2 diabetes mellitus: A systematic review for the U.S. Preventive Services Task Horce. Ann Intern Med. 2015;162:765–776.
    1. Simmons R.K., Echouffo-Tcheugui J.B., Sharp S.J., Sargeant L.A., Williams K.M., Prevost A.T. Screening for type 2 diabetes and population mortality over 10 years (ADDITION- Cambridge): A cluster randomised controlled trial. Lancet. 2012;380:1741–1748.
    1. Knowler W.C., Barrett-Connor E., Howler S.E., Hamman R.F., Lachin J.M., Walker E.A., Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
    1. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350.
    1. Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A.D., Vijay V., Indian Diabetes Prevention Programme (IDPP) The Indian Diabetes Prevention Programme shows that lifestyle modiÞcation and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) Diabetologia. 2006;49:289–297.
    1. Watanabe M., Yamaoka K., Yokotsuka M., Tango T. Randomized controlled trial of a new dietary education program to prevent type 2 diabetes in a high-risk group of Japanese male workers. Diabetes Care. 2003;26:3209–3214.
    1. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An ZX Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–544.
    1. Dyson P.A., Hammersley M.S., Morris R.J., Holman R.R., Turner R.C. The Hasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism. 1997;46:50–55.
    1. Norris S.L., Kansagara D., Bougatsos C., Nygren P., Hu R. Agency for Healthcare Research and Quality; Rockville, MD: 2008. Screening for type 2 diabetes: Update of 2003 systematic evidence review for the U.S. Preventive Services Task Horce. Evidence synthesis n.° 61.
    1. Hemmingsen B., Giménez-Pérez G., Mauricio D., Roqué I., Figuls M., Metzendorf M.I., Richter B. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;12:CD003054.
    1. Barry E., Roberts S., Oke J., Vijayaraghavan S., Normansell R., Greenhalgh T. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: Systematic review and meta-analysis of screening tests and interventions. BMJ. 2017;356:i6538.
    1. Costa B., Barrio H., Piñol J.L., Cabré J.J., Mundet X., Sagarra R., DE-PLAN-CAT/PREDICE Research Group. Shifting from glucose diagnosis to the new HbA1c diagnosis reduces the capability of the Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities within a real-life primary healthcare preventive strategy. BMC Med. 2013;11:45.
    1. Soriguer F., Valdés S., Tapia M.J., Esteva I., Ruiz de Adana M.S., Almaraz M.C. Validación del FINDRISC (FINnish Diabetes Risk SCore) para la predicción del riesgo de diabetes tipo 2 en una población del sur de España. Med Clin (Barc). 2012;138:371–376.
    1. Griffin S.J., Borch-Johnsen K., Davies M.J., Khunti K., Rutten G.E., Sandbæk A. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): A cluster-randomised trial. Lancet. 2011;378:156–167.
    1. Diabetes Prevention Program Research Group, Knowler W.C., Howler S.E., Hamman R.H., Christophi C.A., Hoffman H.J., Brenneman A.T. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–1686.
    1. The Diabetes Prevention Program Research Group Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care. 2012;35:731–737.
    1. Duke S.A., Colagiuri S., Colagiuri R. Individual patient education for people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2009:CD005268.
    1. Cradock K.A., ÓLaighin G., Hinucane H.M., Gainforth H.L., Quinlan L.R., Ginis K.A. Behaviour change techniques targeting both diet and physical activity in type 2 diabetes: A systematic review and meta-analysis. Int J Behav Nutr Phys Act. 2017;14:18.
    1. Zhang K., Yang W., Dai H., Deng Z. Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis. Diabetes Res Clin Pract. 2020;160:108001.
    1. Han Y., Xie H., Liu Y., Gao P., Yang X., Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: A systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18:96.
    1. Wang F., He Y., Zhang R., Zeng Q., Zhao X. Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. Medicine (Baltimore). 2017;96:e7638.
    1. Seong J.M., Choi N.K., Shin J.Y., Chang Y., Kim Y.J., Lee J. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: A population-based cohort study. PLoS One. 2015;10:e0124287.
    1. Ou S.M., Shih C.J., Chao P.W., Chu H., Kuo S.C., Lee Y.J. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med. 2015;163:663–672. doi: 10.7326/M15-0308.
    1. Rao A.D., Kuhadiya N., Reynolds K., Fonseca V.A. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: A meta-analysis of observational studies. Diabetes Care. 2008;31:1672–1678.
    1. Madsen K.S., Kähler P., Kähler L.K.A., Madsbad S., Gnesin F., Metzendorf M.I. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019;4:CD012368.
    1. Maruthur N.M., Tseng E., Hutfless S., Wilson L.M., Suarez-Cuervo C., Berger Z. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2016;164:740–751.
    1. Azoulay L., Suissa S. Sulfonylureas and the risks of cardiovascular events and death: A methodological meta-regression analysis of the observational studies. Diabetes Care. 2017;40:706–714.
    1. Wurm R, Resl M, Neuhold S, Prager R, Brath H, Francesconi C, et al. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles. Heart. 2016;102(19):1544-51.
    1. Bain S., Druyts E., Balijepalli C., Baxter C.A., Currie C.J., Das R. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab. 2017;19:329–335.
    1. Zhuang X.D., He X., Yang D.Y., Guo Y., He J.G., Xiao H.P. Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials. Cardiovasc Diabetol. 2018;17:79.
    1. Varvaki Rados D., Catani Pinto L., Reck Remonti L., Bauermann Leitão C., Gross J.L. The Association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials [published correction appears in PLoS Med 2016 Jun;13(6):e1002091] PLoS Med. 2016;13:e1001992.
    1. Simpson S.H., Lee J., Choi S., Vandermeer B., Abdelmoneim A.S., Featherstone T.R. Mortality risk among sulfonylureas: A systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3:43–51.
    1. Rosenstock J., Perkovic V., Johansen O.E., Cooper M.E., Kahn S.E., Marx N., CARMELINA Investigators Effect of lina- gliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA. 2019;32:69–79.
    1. Rosenstock J., Kahn S.E., Johansen O.E., Zinman B., Espeland M.A., Woerle H.J., for the CAROLINA Investigators Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes. The CAROLINA Randomized Clinical Trial. JAMA. 2019;322:1155–1166.
    1. Perkovic V., Jardine M.J., Neal B., Bompoint S., Heerspink H.J.L., Charytan D.M. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306.
    1. Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., DECLARE-TIMI 58 Investigators Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357.
    1. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019;139(22):2516-27.
    1. McMurray J.J.V., Solomon S.D., Inzucchi S.E., Køber L., Kosiborod M.N., Martinez F.A., DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.
    1. Monami M., Dicembrini I., Mannucci E. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54:19–36.
    1. Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. doi: 10.1056/NEJMoa1603827.
    1. Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A., SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
    1. Hernandez A.F., Green J.B., Janmohamed S., D’Agostino R.B., Sr., Granger C.B., Jones N.P., Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529.
    1. Pfeffer M.A., Claggett B., Diaz R., Dickstein K., Gerstein H.C., Køber L.V., ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
    1. Holman R.R., Bethel M.A., Mentz R.J., Thompson V.P., Lokhnygina Y., Buse J.B., EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239.
    1. Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Lakshmanan M., Pais P., REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
    1. Husain M., Birkenfeld A.L., Donsmark M., Dungan K., Eliaschewitz F.G., Franco D.R., PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–851.
    1. Mannucci E., Monami M. Cardiovascular safety of incretin based therapies in type 2 diabetes: Systematic review of integrated analyses and randomized controlled trials. Adv Ther. 2017;34:1–40.
    1. Monami M., Zannoni S., Pala L., Silverii A., Andreozzi F., Sesti G. Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta- analysis of randomized controlled trials. Int J Cardiol. 2017;240:414–421.
    1. Zelniker T.A., Wiviott S.D., Raz I., Im K., Goodrich E.L., Furtado R.H.M. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139:2022–2031.
    1. Kristensen S.L., Rørth R., Jhund P.S., Docherty K.F., Sattar N., Preiss D. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials [published correction appears in Lancet Diabetes Endocrinol 2020 Mar;8(3):e2] Lancet Diabetes Endocrinol. 2019;7:776–785.
    1. Turnbull F.M., Abraira C., Anderson R.J., Byington R.P., Chalmers J.P., Control Group Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–2298.
    1. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772.
    1. Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M., Lafont S., Bergeonneau C., Kassaï B. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Metaanalysis of randomised controlled trials. BMJ. 2011;343:d4169.
    1. Hemminsen B., Luund S., Gluud C., Vaag A., Almdal T., Hemmingsen C. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898.
    1. Seidu S., Achana H.A., Gray J., Davies M.J., Khunti K. Systematic review or meta-analysis. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: A meta-analysis of randomized control trials. Diabet Med. 2016;33:280–289.
    1. Rodríguez-Poncelas A., Barrot-de la-Puente J., Coll de Tuero G., López-Arpí C., Vlacho B., Lopéz-Simarro F. Glycaemic control and treatment of type 2 diabetes in adults aged 75 years or older. Int J Clin Pract. 2018;72:e13075.
    1. Orozco-Beltrán D., Navarro-Pérez J., Cebrián-Cuenca A.M., Álvarez-Guisasola F., Caride-Miana E., Mora G. The influence of hemoglobin A1c levels on cardiovascular events and all-cause mortality in people with diabetes over 70 years of age. A prospective study [published online ahead of print, 2020 Jun 27] Prim Care Diabetes. 2020;S1751-9918:30215–30221.
    1. Laiteerapong N., Ham S.A., Gao Y., Moffet H.H., Liu J.Y., Huang E.S. The legacy effect in type 2 diabetes: Impact of Early Glycemic Control On Future Complications (The Diabetes & Aging Study) Diabetes Care. 2019;42:416–426.
    1. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
    1. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008:580–591.
    1. Seidu S., Cos X., Brunton S., Harris S.B., Jansson S.P.O., Mata-Cases M. A disease state approach to the pharmacological management of type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe [published online ahead of print, 2020 Jun 9] Prim Care Diabetes. 2020;S1751-9918:30189–30193.
    1. Álvarez-Guisasola F., Orozco-Beltrán D., Cebrián-Cuenca A.M., Ruiz Quintero M.A., Angullo Martínez E. Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2. Aten Primaria. 2019;51:442–451.
    1. Mata-Cases M., Franch-Nadal J., Real J., Mauricio D. Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: A population-based study. BMJ Open. 2016;6:e012463.
    1. Whyte M.B., Hinton W., McGovern A., van Vlymen J., Ferreira F., Calderara S. Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis. PLoS Med. 2019;16:e1002942.
    1. Carratalá-Munuera M.C., Gil-Guillen V.F., Orozco-Beltran D., Navarro-Pérez J., Caballero-Martínez F., Alvarez-Guisasola F., “Integrated Management of Type 2 Diabetes Mellitus” Research Group Barriers associated with poor control in Spanish diabetic patients. A consensus study. Int J Clin Pract. 2013;67:888–894.
    1. García-Pérez L.E., Alvarez M., Dilla T., Gil-Guillén V., Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4:175–194.
    1. Iglay K., Cartier S.E., Rosen V.M., Zarotsky V., Rajpathak S.N., Radican L. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin. 2015;31:1283–1296.
    1. Dworak M., Bader G., Giani G. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: A primary care database analysis. Diabetes Obes Metab. 2013;15:55–61.
    1. Khunti K., Seidu S., Kunutsor S., Davies M. Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: A meta-analysis. Diabetes Care. 2017;40:1588–1596.
    1. Pepió Vilaubí J.M., Orozco-Beltrán D., Gonçalves A.Q., Rodriguez Cumplido D., Aguilar Martin C., Lopez-Pineda A. Adherence to European clinical practice guidelines for secondary prevention of cardiovascular disease: A cohort study. Int J Environ Res Public Health. 2018;15:1233.
    1. Khunti K., Gomes M.B., Pocock S., Shestakova M.V., Pintat S., Fenici P. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes Obes Metab. 2018;20:427–437.
    1. Mata-Cases M., Franch-Nadal J., Real J., Gratacòs M., López-Simarro F., Khunti K. Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment. Diabetes Obes Metab. 2018;20:103–112.
    1. Kotseva K., Wood D., de Backer G., de Bacquer D., Pyorala K., Keil U., EUROASPIRE Study Group EUROASPIRE III: A survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121–137.
    1. Kotseva K., Wood D., de Backer G., de Bacquer D., Pyorala K., Reiner ¥, EUROASPIRE Study Group EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010;17:530–540.
    1. Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., Antithrombotic Trialists’ (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.
    1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet. 1996;348:1329–1339.
    1. Huentes B., Gallego J., Gil-Núñez A., Morales A., Purroy H., Roquer J., Committee of the Cerebrovascular Diseases Study Group of The Spanish Neurological. Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type. Neurología. 2014;29:168–183.
    1. Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Health Technol Assess. 2013;17(43):1-253.
    1. De Berardis G., Sacco M., Strippoli G.H., Pellegrini H., Graziano G., Tognoni G. Aspirin for primary prevention of cardiovascular events in people with diabetes: Meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531. Erratum in: BMJ. 2010;340:c374.
    1. Raju N., Sobieraj-Teague M., Hirsh J., O’Donnell M., Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124:621–629.
    1. Zheng S.L., Roddick A.J. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: A systematic review and meta-analysis. JAMA. 2019;321:277–287.
    1. De Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89–95.
    1. Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Erqou S., Sattar N. Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:209–216.
    1. Butalia S., Leung A.A., Ghali W.A., Rabi D.M. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: A systematic review and metaanalysis. Cardiovasc Diabetol. 2011;10:25.
    1. Stavrakis S., Stoner J.A., Azar M., Wayangankar S., Thadani U. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Am J Med Sci. 2011;341:1–9.
    1. Younis N., Williams S., Ammori B., Soran H. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A meta-analysis. Expert Opin Pharmacother. 2010;11:1459–1466.
    1. Zhang C., Sun A., Zhang P., Wu C., Zhang S., Fu M. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2010;87:211–218.
    1. HOT Study Group. Hansson L., ¥anchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762.
    1. Jardine M.J., Ninomiya T., Perkovic V., Cass A., Turnbull H., Gallagher M.P. Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56:956–965.
    1. Palmer S.C., di Micco L., Razavian M., Craig J.C., Perkovic V., Pellegrini H. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: A systematic review and metaanalysis. Ann Intern Med. 2012;156:445–459.
    1. Windecker S., Kolh P., Alfonso H., Collet J.P., Cremer J., Halk V., 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Horce on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J. 2014;35:2541–2619.
    1. Roffi M., Patrono C., Collet J.P., Mueller C., Valgimigli M., Andreotti H., ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Horce for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) Eur Heart J. 2016;37:267–315.
    1. Valgimigli M., Bueno H., Byrne R.A., Collet J.P., Costa H., Jeppsson A., ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies 2017 ESC focused on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Horce for dual antiplatelet therapy in coronary artery disease. Eur Heart J. 2018;39:213–260.
    1. Ibáñez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., ESC Scientific Document Group 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Horce for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J. 2017;39:119–177.
    1. Navarese E.P., Andreotti H., Schulze V., Kolodziejczak M., Buffon A., Brouwer M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: Meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618.
    1. Bhatt D.L., Hox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717.
    1. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375.
    1. Healey J.S., Connolly S.J., Gold M.R., Israel C.W., Van Gelder I.C., Capucci A. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–129.
    1. Gómez-Doblas J.J., Muñiz J., Martín J.J.A., Rodríguez-Roca G., Lobos J.M., Awamleh P., OFRECE study collaborators. Prevalence of atrial fibrillation in Spain OFRECE study results. Rev Esp Cardiol Engl Ed. 2014;67:259–269.
    1. Lobos-Bejarano J.M., del Castillo-Rodríguez J.C., Alemán-Sánchez J.J., Cabrera de León A., Barón-Esquivias G. en nombre de los Investigadores del Estudio FIATE (Situación actual de la FIbrilación auricular en ATención primaria en España). Características de los pacientes y abordaje terapéutico de la fibrilación auricular en atención primaria en España: Estudio FIATE [Patients’ characteristics and clinical management of atrial fibrillation in primary healthcare in Spain: FIATE Study] Med Clin (Barc). 2013;141:279–286.
    1. Verberk W.J., Omboni S., Kollias A., Stergiou G.S. Screening for atrial fibrillation with automated blood pressure measurement: Research evidence and practice recommendations. Int J Cardiol. 2016;203:465–473.
    1. National Institute for Health and Care Excellence. WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension. NICE. 2013 [consultado 26 Jul 2020]. Disponible en: . uk/guidance/mtg13
    1. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. EUROPACE. 2016;18:1609–1678.
    1. National Institute for Health and Care Excellence. Atrial fibrillation: Management. NICE. 2014 [consultado 26 Jul 2020]. Disponible en:
    1. January C.T., Wann L.S., Alpert J.S., Calkins H., Cigarroa J.E., Cleveland J.C., Jr., ACC/AHA Task Force Members. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071–2104.
    1. Wheeldon N.M., Tayler D.I., Anagnostou E., Cook D., Wales C., Oakley G.D.G. Screening for atrial fibrillation in primary care. Heart. 1998;79:50–55.
    1. Taggar J.S., Coleman T., Lewis S., Heneghan C., Jones M. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: A systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23:1330–1338.
    1. Fitzmaurice D.A., Hobbs F.D.R., Jowett S., Mant J., Murray E.T., Holder R. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: Cluster randomised controlled trial. BMJ. 2007;335:383.
    1. Swancutt D., Hobbs R., Fitzmaurice D., Mant J., Murray E., Jowett S. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over: The SAFE study. BMC Cardiovasc Disord. 2004;4:12.
    1. González Blanco V., Pérula de Torres L.A., Martín Rioboó E., Martínez Adell MÁ, Parras Rejano J.M., González Lama J., grupo de estudio colaborativo DOFA-AP. Opportunistic screening for atrial fibrillation versus detecting symptomatic patients aged 65 years and older: A cluster-controlled clinical trial. Med Clin (Barc). 2017;148:8–15.
    1. Jacobs M.S., Kaasenbrood F., Postma M.J., van Hulst M., Tieleman R.G. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace. 2018;20:12–18.
    1. Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383:955–962.
    1. Moran P.S., Teljeur C., Ryan M., Smith S.M. Systematic screening for the detection of atrial fibrillation. Cochrane Database System Rev. 2016:CD009586.
    1. Mairesse G.H., Moran P., van Gelder I.C., Elsner C., Rosenqvist M., Mant J., ESC Scientific Document Group Screening for atrial fibrillation: A European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE) Europace. 2017;19:1589–1623.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner